胃癌淋巴结转移相关外周血MicroRNA分子标记物的临床价值

目的：分析不同时期胃癌患者外周血中MicroRNA（miRNA）的表达差异，以寻找一种特异性高的肿瘤标记物。方法选取2010年5月至2012年12月上海浦东新区人民医院普外科住院治疗的80例胃癌患者，将其按照淋巴结转移数目分为N0组（无淋巴结转移）46例、N3组（淋巴结转移大于7枚）34例，并选取同一时期的体检健康者40例为健康对照组。取外周血进行基因芯片检测，并选择在 N0组与 N3组表达差异显著的 hsa-miR-106a ，采用实时荧光定量聚合酶联反应（qRT-PCR）扩大标本量进行检测。结果 qRT-PCR检测结果显示，N3组的外周血hsa-miR-106a表达水平较N0组及健康对照组明显上调，差异有统计学意义（P＜0．05），但N0组与健康对照组外周血hsa-miR-106a表达水平差异无统计学意义（P＞0．05）。hsa-miR-106a表达水平除了与胃癌淋巴结转移有关外（P＜0．05），与患者性别、年龄、肿瘤大小、部位、组织学类型、肿瘤类型及分化程度都无关（P＞0．05）。结论 hsa-miR-106a在有淋巴结转移的胃癌患者外周血中高表达，可作为胃癌筛查的重要肿瘤标记物。

Analysis of MicroRNA molecular markers correlated with lymph node metastasis of gastric cancer

Objective To analyze the expression differences of MicroRNA （miRNA） in peripheral blood of pa-tients with gastric carcinoma at different stages ,and to find tumor markers with high specificity .Methods A total of 80 patients with gastric cancer were divided into N 0 group （without lymph node metastasis ） of 46 cases and N3 group （with metastasis of more than 7 lymph nodes） of 34 cases .A total of 40 healthy subjects were enrolled as con-trol group .miRNA with significantly different expression level between N 0 and N3 group was identified by gene chip analysis ,and quantitative real -time fluorescent polymerase chain reaction （qRT-PCR） were performed for detection of expanded quantity of samples .Results hsa-miR-106a was identified as the miRNA with significantly different ex-pression level between N0 and N3 group ,with higher expression level in N3 group ,compared with N0 group and con-trol group （P＆lt;0 .05） ,but there was no statistical difference between N0 group and control group （P＆gt;0 .05） .Ex-pression level of hsa-miR-106a was correlated with lymph node metastasis of gastric cancer ,but not correlated with gender and age of patents and size ,location ,histological type and general type of tumor （P＆gt;0 .05） .Conclusion Ex-pression level of hsa-miR-106a in patients with lymph node metastasis of gastric cancer might be relatively high , which could be used as tumor marker for screening of gastric cancer .